Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study

Carlo Salvarani, Gianluigi Bajocchi, Pamela Mancuso, Elena Galli, Francesco Muratore, Luigi Boiardi, Mariagrazia Catanoso, Nicolò Pipitone, Giulia Cassone, Nicolò Girolimetto, Stefania Croci, Luca Cimino, Federeica Gradellini, Marina Beltrami, Vito Di Lernia, Giovammi Dolci, Marco Massari, Anna Maria Marata, Massimo Costantini, Paolo Giorgi Rossi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)986-988
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume79
Issue number7
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Abatacept/therapeutic use
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Antirheumatic Agents/therapeutic use
  • Azetidines/therapeutic use
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections/epidemiology
  • Disease Susceptibility
  • Female
  • Hospitalization/statistics & numerical data
  • Humans
  • Interleukin 1 Receptor Antagonist Protein/therapeutic use
  • Italy/epidemiology
  • Janus Kinase Inhibitors/therapeutic use
  • Logistic Models
  • Male
  • Middle Aged
  • Pandemics
  • Piperidines/therapeutic use
  • Pneumonia, Viral/epidemiology
  • Proportional Hazards Models
  • Pyrimidines/therapeutic use
  • Pyrroles/therapeutic use
  • Rheumatic Diseases/drug therapy
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index
  • Sulfonamides/therapeutic use
  • Tumor Necrosis Factor Inhibitors/therapeutic use
  • Ustekinumab/therapeutic use

Cite this